Overall, this study demonstrates that PKCε upregulation occurs frequently in AML, is a poor prognostic indicator associated with reduced patient responses to induction therapy and could contribute to poor outcomes by decreasing leukemia cell DNR chemosensitivity through promoting P-GP expression and drug efflux. This evidence concerns the gene PRKCE and acute myeloid leukemia.